Bbva Compass Bancshares Inc. Cuts Stake in CVS Health Corp (CVS)

Bbva Compass Bancshares Inc. lessened its position in shares of CVS Health Corp (NYSE:CVS) by 7.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 47,485 shares of the pharmacy operator’s stock after selling 4,022 shares during the quarter. Bbva Compass Bancshares Inc.’s holdings in CVS Health were worth $3,862,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Pathstone Family Office LLC lifted its stake in shares of CVS Health by 341.0% during the second quarter. Pathstone Family Office LLC now owns 1,270 shares of the pharmacy operator’s stock valued at $2,353,000 after acquiring an additional 982 shares during the period. Fieldpoint Private Securities LLC lifted its stake in shares of CVS Health by 333.3% during the second quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after acquiring an additional 1,000 shares during the period. Arcadia Investment Management Corp MI lifted its stake in shares of CVS Health by 119.6% during the third quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock valued at $108,000 after acquiring an additional 726 shares during the period. MPS Loria Financial Planners LLC acquired a new position in shares of CVS Health during the second quarter valued at $119,000. Finally, Gemmer Asset Management LLC increased its holdings in CVS Health by 15.3% in the second quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock valued at $121,000 after purchasing an additional 200 shares during the last quarter. 81.63% of the stock is currently owned by institutional investors and hedge funds.

Shares of CVS Health Corp (NYSE:CVS) opened at $73.20 on Thursday. CVS Health Corp has a fifty-two week low of $66.45 and a fifty-two week high of $84.72. The stock has a market capitalization of $74,150.00, a PE ratio of 15.12, a price-to-earnings-growth ratio of 1.28 and a beta of 0.90. The company has a quick ratio of 0.55, a current ratio of 1.05 and a debt-to-equity ratio of 0.67.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.01. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The company had revenue of $46.18 billion during the quarter, compared to the consensus estimate of $46.17 billion. During the same period in the prior year, the company earned $1.64 earnings per share. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year. sell-side analysts predict that CVS Health Corp will post 5.9 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 2nd. Shareholders of record on Wednesday, January 24th will be issued a $0.50 dividend. The ex-dividend date is Tuesday, January 23rd. This represents a $2.00 annualized dividend and a dividend yield of 2.73%. CVS Health’s dividend payout ratio (DPR) is currently 41.32%.

A number of equities research analysts recently commented on CVS shares. Needham & Company LLC reiterated a “hold” rating on shares of CVS Health in a report on Sunday, September 10th. Oppenheimer reiterated a “buy” rating and issued a $95.00 price objective on shares of CVS Health in a report on Monday, October 9th. Leerink Swann reiterated an “outperform” rating and issued a $85.00 price objective (down previously from $90.00) on shares of CVS Health in a report on Tuesday, November 7th. SunTrust Banks set a $85.00 price objective on CVS Health and gave the company a “buy” rating in a report on Thursday, October 12th. Finally, Citigroup set a $76.00 price objective on CVS Health and gave the company a “hold” rating in a report on Monday, December 4th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $86.51.

In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of the stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $75.00, for a total value of $2,208,375.00. Following the completion of the sale, the executive vice president now directly owns 15,556 shares in the company, valued at $1,166,700. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.61% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Bbva Compass Bancshares Inc. Cuts Stake in CVS Health Corp (CVS)” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.com-unik.info/2018/01/04/bbva-compass-bancshares-inc-cuts-stake-in-cvs-health-corp-cvs.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit